Atomoxetine Hydrochloride (Strattera)

A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

Also Known As:

Strattera; Atomoxetine; Atomoxetine HCl; LY 139603; N-methyl-gamma-(2-methylphenoxy)benzenepropanamine hydrochloride; Tomoxetine; Tomoxetine Hydrochloride, (+)-isomer - T351671; Tomoxetine Hydrochloride, (+-)-isomer; Tomoxetine Hydrochloride, (-)-isomer; 139603, LY; HCl, Atomoxetine; Hydrochloride, Atomoxetine

Networked: 1222 relevant articles (257 outcomes, 425 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Propylamines: 1
    - Atomoxetine Hydrochloride: 1222

Experts

1.	Allen, Albert J: 40 articles (01/2017 - 01/2002)
2.	Kratochvil, Christopher J: 27 articles (10/2012 - 01/2002)
3.	Michelson, David: 27 articles (11/2008 - 01/2002)
4.	Biederman, Joseph: 26 articles (01/2013 - 01/2002)
5.	Spencer, Thomas J: 25 articles (01/2011 - 01/2002)
6.	Dittmann, Ralf W: 22 articles (12/2017 - 01/2004)
7.	Newcorn, Jeffrey H: 22 articles (07/2017 - 07/2002)
8.	Schacht, Alexander: 21 articles (07/2015 - 12/2007)
9.	Adler, Lenard A: 20 articles (01/2020 - 02/2005)
10.	Escobar, Rodrigo: 19 articles (01/2020 - 06/2009)

Related Diseases

1.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 09/01/2017 - "The objective of the present study was to conduct the most comprehensive meta-analysis to date evaluating the efficacy of atomoxetine in reducing core symptomatology of ADHD according to parent report. " 02/01/2007 - "Quality of life of children/adolescents with ADHD was extremely compromised at baseline (CHIP-CE total t-scores: atomoxetine, 23.2 +/- 12.2; SCT, 23.9 +/- 11.0), and improved during the 10-week study for both groups; the CHIP-CE score was statistically significantly higher for patients treated with atomoxetine (38.4 +/- 1.3) compared with SCT (30.8 +/- 1.3) at week 10 (p < 0.001). " 02/01/2015 - "Evidence indicates that psychostimulants, alpha-2 agonists, and atomoxetine can be beneficial for disruptive and aggressive behaviours in addition to core ADHD symptoms; however, psychostimulants generally provide the most benefit." 03/01/2011 - "The most commonly used agents include several stimulants and atomoxetine, which have demonstrated significant, though similar, efficacy for ADHD versus placebo. " 04/08/2002 - "The efficacy of the highly selective noradrenergic reuptake inhibitor, tomoxetine, in treating ADHD symptoms supports the system's role in ADHD and points to the norephinephrine transporter as a candidate gene. "
2.	Oppositional Defiant Disorder 02/01/2008 - "It remains uncertain, however, whether atomoxetine exerts a specific and enduring effect on oppositional defiant disorder symptoms." 02/01/2008 - "Repeated-measures analysis demonstrated a statistically significant difference favoring atomoxetine over placebo in the reduction of Swanson, Nolan, and Pelham Rating Scale-Revised oppositional defiant disorder total scores. " 08/01/2004 - "Treatment with atomoxetine, lower HRQL baseline score, no history of stimulant use, and absence of oppositional defiant disorder were all associated with improvements in psychosocial functioning. " 09/01/2009 - "Therapy with atomoxetine has been associated with statistically significant improvements in symptoms of oppositional defiant disorder in most, but not all, studies. " 02/01/2008 - "This study confirms previous findings that patients with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder show statistically and clinically significant improvement in attention-deficit/hyperactivity disorder symptoms and global clinical functioning when treated with atomoxetine. "
3.	Obstructive Sleep Apnea 12/01/2022 - "This study provides additional support that a pharmacological intervention for obstructive sleep apnea, namely the combination of atomoxetine and aroxybutynin, offers promising results. " 10/09/2023 - "The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial." 07/01/2008 - "Atomoxetine improved sleepiness and the CGI in patients with mild to moderate obstructive sleep apnea with sleepiness. " 07/01/2008 - "Atomoxetine improves sleepiness and global severity of illness but not the respiratory disturbance index in mild to moderate obstructive sleep apnea with sleepiness." 01/01/2021 - "Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea."
4.	Dyslexia (Alexia) 01/01/2017 - "Atomoxetine-treated dyslexia-only patients compared with placebo patients had significantly greater improvement (p < 0.02) with moderate to approaching high effect sizes (ES) on WJIII Word Attack (ES = 0.72), Basic Reading Skills (ES = 0.48), and Reading Vocabulary (ES = 0.73). " 11/01/2013 - "The atomoxetine-treated dyslexia-only subjects significantly improved from baseline to week 32 on ADHDRS-IV-Parent:Inv Inattentive subscale, K-SCT Parent and Teacher subscales, and WMTB-C Phonological Loop and Central Executive component scores. " 11/01/2013 - "At week 16, atomoxetine treatment resulted in significant (p<0.05) improvement from baseline in subjects with ADHD+D versus placebo on ADHDRS-IV-Parent:Inv Total (primary outcome) and subscales, ADHDRS-IV-Teacher-Version Inattentive subscale, K-SCT Interview Parent and Teacher subscales, and WMTB-C Central Executive component scores; in subjects with Dyslexia-only, atomoxetine versus placebo significantly improved K-SCT Youth subscale scores from baseline. " 01/01/2017 - "In the atomoxetine-treated ADHD and comorbid dyslexia group, improvement on the CTOPP Elision measure (ES = 0.50) was significantly greater compared with placebo (p < 0.02). " 12/15/2009 - "Though limited by small sample size, group differences in relation to the comparable changes in improvement in ADHD symptoms could suggest that brain systems related to the therapeutic benefit of atomoxetine in reducing ADHD symptoms may be different in individuals with ADHD+D and ADHD without dyslexia. "
5.	Orthostatic Hypotension (Postural Hypotension) 09/01/2015 - "Our data suggest that low-dose atomoxetine is an effective and safe agent for symptom improvement and blood pressure control in elderly patients with primary orthostatic hypotension. " 01/01/2018 - "Evaluating the effectiveness of atomoxetine for the treatment of primary orthostatic hypotension in adults." 09/01/2015 - "This report discusses a case of atomoxetine use for 10 weeks in an elderly patient with primary orthostatic hypotension. " 09/01/2015 - "Atomoxetine for Orthostatic Hypotension in an Elderly Patient Over 10 Weeks: A Case Report." 03/01/2023 - "Effects of Atomoxetine for the Treatment of Neurogenic Orthostatic Hypotension in Patients With Alpha-synucleinopathies: A Systematic Review of Randomized Controlled Trials and a Focus-Group Discussion."

Related Drugs and Biologics

1.	Methylphenidate (Ritalin)
2.	Norepinephrine (Noradrenaline)
3.	Guanfacine (Tenex)
4.	Amphetamine (Amfetamine)
5.	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)
6.	oxybutynin (Tavor)
7.	Clonidine (ST 155)
8.	Amphetamines
9.	Dextroamphetamine (Dexedrine)
10.	Risperidone (Risperdal Consta)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Speech Therapy (Therapy, Speech)
4.	Aftercare (After-Treatment)
5.	Neurofeedback